Bates White expert advises Thermo Fisher in successful acquisition of Solventum’s purification and filtration business
In February 2025, Thermo Fisher Scientific, Inc, a manufacturer and supplier of life sciences products, announced it would acquire the purification and filtration arm of Solventum, a provider of purification and filtration technologies used in the production of biologics and in medical technologies and industrial applications. Both companies operate globally and focus on products using different technologies in the bioprocessing workflows.
Axinn, counsel for Thermo Fisher, retained Nicholas Hill to provide advocacy support on behalf of Thermo Fisher in its $4.1 billion acquisition during the Federal Trade Commission (FTC) investigation. The team contributed to submissions to the FTC, demonstrating why input foreclosure was unlikely as a result of the proposed transaction.
The FTC allowed the HSR waiting period to expire and the transaction was successfully completed in September 2025.
Dr. Hill was supported in his work by Mico Mao and Prerna Rakheja.